Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North ...

The US Food and Drug Administration (FDA) has approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for the treatment of certain adult patients with metastatic ...

Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ® (sotorasib) in combination with Vectibix ® (panitumumab ...

approval for its LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination therapy for treating adults with KRAS G12C-mutated metastatic colorectal cancer. "Amgen opens new drug substance ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

M.D., executive vice president of Research and Development at Amgen. 2 "LUMAKRAS plus Vectibix offers a targeted, biomarker-driven combination therapy that helps delay disease progression more ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with ...

3-6 "Designed for dual blockade of KRAS G12C and EGFR pathways, the combination of sotorasib plus panitumumab ... The FDA completed its review of Amgen's supplemental New Drug Application (sNDA ...

M.D., executive vice president of Research and Development at Amgen. 2 "LUMAKRAS plus Vectibix offers a targeted, biomarker-driven combination therapy that helps delay disease progression more ...

According to a statement from the agency on Thursday, Lumakras, also known as sotorasib, will be indicated in the U.S. with Amgen’s (NASDAQ:AMGN) epidermal growth factor receptor (EGFR ...